CA-MATRIXX-SOFTWARE
11.6.2019 10:02:11 CEST | Business Wire | Press release
MATRIXX Software , an innovation powerhouse committed to transforming global commerce, today announced that Roshan, Afghanistan’s leading telecommunications service provider, has selected MATRIXX Digital Commerce to transform their operations and grow revenue.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005211/en/
Roshan is partnering with MATRIXX Software to change the way its six million customers use telecom services by bringing real-time digital experience and personalization for all voice, data and digital services.
MATRIXX has a global customer footprint across Europe, the Middle East, Asia and North America. Roshan selected MATRIXX because it is the only vendor providing a single platform that both protects and grows revenues from traditional prepaid voice and messaging services while also delivering the tools to attract smartphone users and increase data usage. As the digital revolution sweeps through emerging markets, mobile operators need cost effective, scalable solutions that improve their existing operating portfolios while building for the future of smartphones and digital service revenues.
In a signing ceremony in Dubai, UAE, Roshan’s CEO Karim Khoja said, “Since our founding, Roshan has always embraced implementing new technologies and applications to provide our customers with the best experience. This partnership with MATRIXX Software showcases that the digital experience is quickly becoming a reality in Afghanistan.”
“Afghanistan’s communications infrastructure has come a long way in 16 years and Roshan has played and continues to play a significant role in making that happen,” said Dave Labuda, MATRIXX Software co-founder and CEO. “It is only natural that Roshan is leading the way into a new era of digital connectivity. We are proud to be a part of helping Roshan deliver the future of customer experience and service innovation that Roshan aims to bring to their customers.”
Built entirely from scratch, the multi-patented, award-winning MATRIXX Digital Commerce Platform enables a digital-first reinvention of Telco BSS. It brings together traditionally separate network and IT functions into a single platform including product design and lifecycle management, customer engagement, service delivery and monetization. Built for digital, the MATRIXX Digital Commerce Platform offers operators the agility and seamless scalability required to compete and win now and in the future.
Roshan has always been a pioneer in leveraging its robust network infrastructure and technology to support the government and the people of Afghanistan. These include the launch of Afghanistan’s first ever mobile money service, M-Paisa, which has contributed to increasing financial transparency and financial inclusion. Roshan also launched the first Telemedicine program in Afghanistan in 2007, linking hospitals in Badakhshan, Bamiyan and Kandahar provinces to the French Medical Institute for Children and Mothers (FMIC) in Kabul, one of the most modern hospitals in the country. Since its launch, almost 30,000 patients across Afghanistan have received treatment through this telemedicine link.
About Roshan
Roshan (Telecom Development Company Afghanistan Ltd) is Afghanistan's leading total communications provider with 6 million active subscribers and a network that covers over 287 districts and cities in all of the country's 34 provinces.
Roshan is a true Afghanistan success story, serving as a catalyst for economic growth and actively contributing to the country’s long-term development. Since its inception in 2003, Roshan has invested approximately $750 million in Afghanistan and is the country’s single largest private investor and taxpayer, contributing approximately five percent of the Afghan government's overall domestic revenue. Roshan directly employs around 900 people, 20 percent of whom are women, and provides indirect employment to more than 35,000 people. Roshan is deeply committed to Afghanistan’s reconstruction and development.
The Aga Khan Fund for Economic Development (AKFED), part of the Aga Khan Development Network (AKDN), is a major shareholder of Roshan and promotes private initiatives and building economically sound enterprises in the developing world. Also owned in part by Monaco Telecom International (MTI) and Telia, Roshan brings international expertise to the country and is committed to the highest standards of network quality and coverage for the people of Afghanistan.
To learn more about Roshan visit www.roshan.af or http://www.facebook.com/RoshanConnects . You can also follow us on Twitter @roshanconnects .
About MATRIXX Software
MATRIXX Software provides next-generation, cloud native digital commerce solutions that transform how companies do business. Serving many of the world’s largest communications companies, IoT players and emerging digital service providers, MATRIXX is committed to delivering a modern commerce platform that easily scales to support global market places and consumption-based services. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to reinvent themselves and succeed as a digital leader.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005211/en/
Contact:
Mercury Global Partners for MATRIXX Software Natalee Gibson, Managing Director matrixx@mercuryglobalpartners.com +1 720 648 5784
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom